IMUGENE LTD (IUGNF:OTCMKTS)
$0.107 0 (0%)
Analysed IMUGENE LTD (IUGNF:OTCMKTS) News Sources
Imugene lands ASCO oral slot in high-profile azer-cel milestone
01-04-2026
proactiveinvestors.com
Imugene launches $20M capital raise to advance azer-cel clinical program
11-03-2026
proactiveinvestors.com
Imugene highlights azer-cel progress as trial patient enters remission
10-03-2026
proactiveinvestors.com
Imugene reports strong early response rates for azer-cel in lymphoma study
10-03-2026
proactiveinvestors.com
Imugene to showcase azer-cel data at major US healthcare conference
26-02-2026
proactiveinvestors.com
Imugene secures $2.7m R&D tax refund to support clinical programs
25-02-2026
proactiveinvestors.com
Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours
28-11-2025
yahoo.com
Imugene Announces Outstanding Response Rates from the Phase 1b Trial of the Azer-cel Allogeneic CAR T in 3L+ DLBCL
14-07-2025
yahoo.com
ASX Penny Stocks: Frontier Digital Ventures And 2 Other Promising Picks
10-06-2025
yahoo.com
ASX Penny Stocks Spotlight: Berkeley Energia And Two More To Consider
27-04-2025
yahoo.com
What is the current price of IMUGENE LTD (IUGNF:OTCMKTS)?
The current price of IMUGENE LTD (IUGNF:OTCMKTS) is $0.107.
IMUGENE LTD (IUGNF:OTCMKTS) absolute price change since previous trading day?
The absolute price change of IMUGENE LTD (IUGNF:OTCMKTS) since the previous trading day is $0.
IMUGENE LTD (IUGNF:OTCMKTS) percentage price change since previous trading day?
The percentage price change of IMUGENE LTD (IUGNF:OTCMKTS) since the previous trading day is 0%.
What is the most recent average sentiment score for IMUGENE LTD (IUGNF:OTCMKTS)?
The most recent average sentiment score for IMUGENE LTD (IUGNF:OTCMKTS) is 84 out of 100.
What is the most recent average sentiment for IMUGENE LTD (IUGNF:OTCMKTS)?
The most recent sentiment for IMUGENE LTD (IUGNF:OTCMKTS) is .
SEC-8K** Filing Available For IMUGENE LTD (IUGNF:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.